Linked Life Data

15289354

Source:http://linkedlifedata.com/resource/pubmed/id/15289354

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
15
pubmed:dateCreated
2004-8-3
pubmed:abstractText
Cervical cancer is the possible outcome of genital infection with high-risk human papillomavirus (HPV) and is preceded by a phase of persistent HPV infection during which the host immune system fails to eliminate the virus. Fortunately, the majority of genital HPV infections are cleared before the development of (pre)malignant lesions. Analysis of CD4+ T-helper (Th) immunity against the E2, E6, and E7 antigens of HPV16 in healthy women revealed strong proliferative E2- and E6-specific responses associated with prominent IFN-gamma and interleukin 5 secretion. This indicates that the naturally arising virus-induced immune response displays a mixed Th1/Th2 cytokine profile. Of all HPV16+ cervical cancer patients, approximately half failed to mount a detectable immune response against the HPV16-derived peptides. The other half of the patients showed impaired HPV16-specific proliferative responses, which generally lacked both IFN-gamma and interleukin 5. This indicates that the HPV16-specific CD4+ T-cell response in cervical cancer patients is either absent or severely impaired, despite a relatively good immune status of the patients, as indicated by intact responses against recall antigens. It is highly conceivable that proper CD4+ T-cell help is important for launching an effective immune attack against HPV because infection of cervical epithelia by this virus is, at least initially, not accompanied by gross disturbance of this tissue and/or strong proinflammatory stimuli. Therefore, our observations concerning the lack of functional HPV16-specific CD4+ T-cell immunity in patients with cervical cancer offer a possible explanation for the development of this disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0008-5472
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
64
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5449-55
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:15289354-Adult, pubmed-meshheading:15289354-Aged, pubmed-meshheading:15289354-CD4-Positive T-Lymphocytes, pubmed-meshheading:15289354-Cervical Intraepithelial Neoplasia, pubmed-meshheading:15289354-DNA-Binding Proteins, pubmed-meshheading:15289354-Female, pubmed-meshheading:15289354-Humans, pubmed-meshheading:15289354-Immunity, Cellular, pubmed-meshheading:15289354-Interferon-gamma, pubmed-meshheading:15289354-Interleukin-5, pubmed-meshheading:15289354-Middle Aged, pubmed-meshheading:15289354-Oncogene Proteins, Viral, pubmed-meshheading:15289354-Papillomaviridae, pubmed-meshheading:15289354-Papillomavirus Infections, pubmed-meshheading:15289354-Repressor Proteins, pubmed-meshheading:15289354-T-Lymphocytes, Helper-Inducer, pubmed-meshheading:15289354-Uterine Cervical Neoplasms
pubmed:year
2004
pubmed:articleTitle
Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6.
pubmed:affiliation
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2300 RC Leiden, the Netherlands.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't